Good Exit: Crowdfunded Company Celixir Delivers 2.7X Returns for Early Shareholders in Buy-Back Offer
Biotech company Celixir has initiated a share-back for early investors. The company is offering shareholders a 2.7x return if they accept the offer. According to the company, 18% of Celixir shareholders have decided to accept the offer with the remaining holding their shares with the… Read More
Read more in: Offerings, Global, Investment Platforms and Marketplaces | Tagged ajan reginald, biomed, celixir, cell therapy, crowdcube, health, luke lang, medical, uk, united kingdom